GLP-1 Receptor Agonists Show No Excess Bowel Obstruction Risk
This large Japanese cohort provides reassurance that initiating glucagon-like peptide-1 receptor agonists does not raise one-year bowel obstruction or ileus risk versus sodium-glucose cotransporter 2 inhibitors, even in higher-risk subgroups.
📅 Journal publication: Nov 2026(online Aug 9, 2026)·Last updated: Aug 13, 2026
GLP-1 receptor agonists show no increased bowel obstruction risk compared to SGLT2 inhibitors.
Patients and clinicians have raised concerns about the risk of bowel obstruction with glucagon-like peptide-1 receptor agonists (GLP-1RAs), impacting treatment choices for type 2 diabetes. In this large database study, GLP-1RA use was not linked to a higher risk of bowel obstruction or ileus compared to sodium-glucose cotransporter 2 inhibitors (SGLT2is), with a hazard ratio of 0.80. The findings reassure clinicians about the gastrointestinal safety of GLP-1RAs compared to SGLT2is for type 2 diabetes, supporting their use without increased concern for bowel obstruction. GLP-1 receptor agonists do not increase bowel obstruction risk versus SGLT2 inhibitors.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Free account, no credit card. Includes 1 full deep analysis every month.
Authors:Matsuo Y, Okada A, Sakamoto T, Yasunaga H
Citation:Matsuo Y, Okada A, Sakamoto T, et al. Bowel Obstruction/Ileus Associated With the Use of Glucagon-Like Peptide-1 Receptor Agonists: A Nationwide Database Study. Diabetes, obesity & metabolism. 2026;28(11):9941-9954. doi:10.1111/dom.71189